Merck (MRK) announces the US FDA has approved LIPFENDRA tablets 20 mg as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH; Phase 3 trials cut LDL-C between 56-59%
#GERMANY#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#FDA#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#US EQUITIES